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BACKGROUND: Combined focal adhesion kinase (FAK) and MEK inhibition may provide greater anticancer effect than FAK
monotherapy.
METHODS: This dose-ﬁnding phase Ib study (adaptive 3+ 3 design) determined the maximum tolerated dose (MTD) of trametinib
and the FAK inhibitor GSK2256098 in combination. Eligible patients had mesothelioma or other solid tumours with probable
mitogen activated protein kinase pathway activation. Adverse events (AEs), dose-limiting toxicities, disease progression and
pharmacokinetics/pharmacodynamics were analysed.
RESULTS: Thirty-four subjects were enrolled. The GSK2256098/trametinib MTDs were 500 mg twice daily (BID)/0.375 mg once daily
(QD) (high/low) and 250 mg BID/0.5 mg QD (low/high). The most common AEs were nausea, diarrhoea, decreased appetite, pruritus,
fatigue and rash; none were grade 4. Systemic exposure to trametinib increased when co-administered with GSK2256098, versus
trametinib monotherapy; GSK2256098 pharmacokinetics were unaffected by concomitant trametinib. Median progression-free
survival (PFS) was 11.8 weeks (95% CI: 6.1–24.1) in subjects with mesothelioma and was longer with Merlin-negative versus Merlin-
positive tumours (15.0 vs 7.3 weeks).
CONCLUSIONS: Trametinib exposure increased when co-administered with GSK2256098, but not vice versa. Mesothelioma patients
with loss of Merlin had longer PFS than subjects with wild-type, although support for efﬁcacy with this combination was limited.
Safety proﬁles were acceptable up to the MTD.
British Journal of Cancer (2019) 120:975–981; https://doi.org/10.1038/s41416-019-0452-3
BACKGROUND
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase
whose activity is critical for cancer cell proliferation, survival,
migration, and invasion.1 FAK overexpression has been documen-
ted in several solid tumours, including mesothelioma, and
haematological malignancies,1–5 but FAK is detected at low levels
in normal tissues or benign tumours.2 FAK overexpression may
relate to prognosis in various human malignancies3,5 and is
therefore an attractive target for anticancer therapy.
GSK2256098 is a potent, oral, reversible inhibitor of the tyrosine
kinase activity measured by the autophosphorylation site (Tyr 397)
of FAK.6 In preclinical studies, GSK2256098 was demonstrated
to be at least 20 times more active in vitro in Merlin-negative
(encoded by NF-2) mesothelioma cells than in Merlin-positive
cells.6 In a recent phase I study of GSK2256098 monotherapy
for patients with advanced solid tumours, mesothelioma
patients with Merlin-negative tumours had a progression-free
survival (PFS) nearly twice that of Merlin-positive mesothelioma
patients.7
Trametinib is an oral, small molecule inhibitor of MEK1/2.8
MEK1/2 is an enzyme within the mitogen activated protein kinase
(MAPK) or RAS/RAF/MEK/ERK pathway. Activation of ERK is
commonly observed in cancers, such as mesothelioma, where it
occurs in 75% of patients.9–11 We hypothesised that a combina-
tion of FAK and MEK inhibition may provide greater anticancer
effect than FAK monotherapy, supported by preclinical evidence
of synergistic growth inhibition and cell death between
GSK2256098 and trametinib across a range of mesothelioma cell
lines (GSK Internal data; manuscript in preparation).
This study aimed to identify the maximum tolerated doses
(MTD) of GSK2256098 and trametinib when administered in
combination and to examine the safety, pharmacokinetics,
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pharmacodynamics, and clinical activity of this combination in
patients with mesothelioma or other solid tumours.
METHODS
Study design
This multipart phase I study (NCT01938443) was conducted at
three centres in the UK, and one in France between 7 November
2013 and 24 June 2016.
Part 1 aimed to identify a low GSK2256098/high trametinib and
a high GSK2256098/low trametinib MTD, using a standard
adaptive 3+ 3 design. Starting doses were GSK2256098 500mg
orally twice daily (BID), 50% of the single-agent MTD, and
trametinib 1 mg orally once daily (QD), 50% of the recommended
monotherapy dose.7,12 Dose de-escalation was followed if the
initial doses exceeded the MTD exposure. GSK2256098 was
administered with a light meal to limit nausea while trametinib
was administered ≥2 h after a meal as per the prescription
information. Patients remained on study medications until disease
progression, adverse events (AE) warranting discontinuation, or
withdrawal of consent.
Once each dose combination had been cleared for safety, two
to three additional subjects were enrolled in a trailing pharma-
codynamic cohort. Mandatory pre- and post-treatment biopsies
were obtained from these subjects. The planned Part 2 expansion
cohort study was cancelled after review of results from Part 1.
Patient selection
Subjects were eligible for the study if they were aged ≥18 years, had
mesothelioma or solid tumours with a high likelihood of MAPK
pathway activation, and had received ≥1 prior course of chemother-
apy. Other key eligibility criteria included Eastern Cooperative
Oncology Group (ECOG) performance status 0–1; adequate
haematologic, hepatic, and renal function; ability to swallow oral
medication; and left ventricular ejection fraction (LVEF) at or above
the lower limit of normal. Female patients with childbearing
potential were asked to comply with protocol-speciﬁed contra-
ceptive measures, and male patients with female partners of
childbearing potential needed to have had a prior vasectomy or
agree to use effective contraception. Patients with symptomatic
leptomeningeal or brain metastases were excluded, as were patients
with active interstitial lung disease or pneumonitis; a history of
retinal vein occlusion or central serous retinopathy; current use of
warfarin; history or evidence of cardiovascular risk; and presence of
active gastrointestinal disease or other condition that may interfere
with the pharmacokinetics of the drugs.
Dose-limiting toxicity
AEs were assessed throughout the study using the National
Cancer Institute Common Terminology Criteria for Adverse Events
v4.0 guidelines.13 An AE was considered a dose-limiting toxicity
(DLT) if it had a causal or possible causal relationship to study
treatment within the ﬁrst 28 days and met the following criteria:
≥Grade 3 non-haematologic toxicity not controlled by routine
supportive measures; Grade 4 neutropenia lasting >5 days; febrile
neutropenia of any grade; Grade 4 thrombocytopenia;
alanine aminotransferase >3x upper limit of normal (ULN) with
bilirubin >2x ULN; any toxicity that resulted in missing ≥14
consecutive or non-consecutive days of scheduled dosing during
the initial 28-day period; any Grade 2 toxicity that, in the
investigator’s judgement, would be dose limiting.
Pharmacokinetic analysis
Blood samples for pharmacokinetic analysis were collected prior
to morning dosing of GSK2256098 on Day 15, and at 1, 1.5, 2, 4, 6,
8 h after the morning dose of GSK2256098. Trametinib was
administered immediately after the 1.5-hour pharmacokinetic
sample was collected.
For PK analysis of trametinib, blood samples were taken via an
indwelling cannula (or by direct venepuncture), collected into a di-
potassium ethylenediaminetetraacetic acid (K2-EDTA) tube and
immediately placed on water ice. Blood samples stored on wet ice
were centrifuged within 1 h of collection at approximately 1500 g for
10min at 4 °C. Supernatant plasma was transferred to a 3.6mL Nunc
tube and stored at 20 °C before shipment. Samples were shipped
frozen on dry ice at agreed timepoints throughout the study to GSK
Pharmaceuticals, Upper Merion, PA, USA, for analysis.
For pharmacokinetic analysis of GSK2256098, blood samples
were taken via an indwelling cannula (or by direct venepuncture),
collected into a K2-EDTA tube and gently mixed by inversion of
the capped tube 3 times until all the EDTA had dissolved into the
sample. Approximately 15 μL blood was then transferred from the
“end-to-end” EDTA capillary tube onto the Whatman FTA DBS
card.
Plasma samples were analysed for trametinib using the
validated analytical method based on liquid-liquid extraction,
followed by high-performance liquid chromatography mass
spectrometry (HPLC-MS/MS) analysis using a TurboIonSpray
interface and multiple reaction monitoring. The lower limit of
quantiﬁcation (LLQ) for trametinib was 0.25 ng/mL using a 50-mL
aliquot of human plasma with a higher limit of quantiﬁcation
(HLQ) of 250 ng/mL. Blood samples were analysed for GSK2256098
using a validated analytical method based on acetonitrile
extraction from dried blood spots on the Whatman FTA DBS card,
followed by HPLC/MS/MS analysis using a TurboIonSpray interface
and multiple reaction monitoring. The LLQ for GSK2256098 was
10 ng/mL using a 3-mm diameter.
GSK2256098 in human blood was also analysed from blood/
water (50/50, v/v) using the validated analytical method based on
protein precipitation followed by HPLC-MS/MS analysis using a
TurboIonSpray interface and multiple reaction monitoring. The
LLQ for GSK2256098 was 10 ng/mL using a 25-μL aliquot of blood/
water (50/50, v/v) with an HLQ of 10 000 ng/mL.
GSK2256098 whole-blood and dry blood spot concentration-time
data as well as trametinib plasma concentration-time data were
analysed by standard noncompartmental methods using Phoenix
WinNonlin version 6.3. Calculations of all Pharmacokinetic para-
meters were based on doses of GSK2256098 and trametinib
administered and actual sampling times from the respective dosing.
Clinical activity
Clinical activity was assessed at baseline and every 8 weeks using
the Response Evaluation Criteria In Solid Tumours (RECIST) 1.1
guidelines;14 mesothelioma was assessed using Modiﬁed RECIST
for Mesothelioma.15
Patient monitoring
Haematology and clinical chemistry laboratory tests were
performed at baseline, Days 1, 8, 15, 22, 29, and every 4 weeks
thereafter. Electrocardiograms were performed at baseline, Days 1,
15, 22, and then every 8 weeks from Day 1.
Tumour biopsy collection and determination of pFAK levels
Paired tumour biopsies were collected prior to dosing on Day 1
and on a day from Days 15 to 22 inclusive. Samples were
analysed for pFAK and total FAK by a proprietary Collaborative-
Enzyme Enhanced Reactive-immunoassay (CEER) (Prometheus
Laboratories, California, USA). A proximity-based immunoassay,
the CEER assay leverages a multiplexed immune-microarray
platform combined with triple-antibody-enzyme channelling
signal ampliﬁcation. Speciﬁc signal ampliﬁcation occurs when
target proteins (pFAK and FAK) captured on an antibody
microarray co-localize with two additional detector-antibodies
linked with channelling enzymes (horseradish peroxidase, HRP,
and glucose oxidase, GO). pFAK levels were normalised to total
FAK. The same technology was leveraged to analyse pERK and
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other MAPK pathway markers. However, a channel enzyme
−enhanced reaction assay for total ERK could not be developed,
so pERK was normalized to total FAK.
Determination of Merlin status
Parafﬁn-embedded, archival tumour samples were required for
all subjects. Merlin (the protein product of the NF2 gene) status
was determined by immunohistochemistry of formalin ﬁxed
parafﬁn-embedded (FFPE) archival samples collected from
subjects with mesothelioma (n= 21). The immunohistochem-
istry assay was developed and conducted by Mosaic Labora-
tories (Lake Forest, California, USA). The primary antibody
included an NF2 antibody (C-18): sc332, Santa Cruz Biotechnol-
ogy (Dallas, Texas, USA). A cell line tissue microarray comprising
a total of six high, moderate, and low Merlin expressors and a
rabbit IgG served as the positive and negative control,
respectively.
Merlin status from archived tumour tissue was recorded as the
percentage of cells that stain at+ 2,+ 3 using the above assay
and then dichotomised as either “Merlin Negative,” if the
percentage of neoplastic cells stained in the intensity staining
category 3 and 2 equalled 0 or was less than 10 in category 2, or
“Merlin Positive” otherwise.
Statistical analysis
No formal statistical hypotheses were tested. An exploratory analysis
of PFS was conducted for the subgroup of subjects with
mesothelioma. PFS was deﬁned as the time from the ﬁrst dose of
study drug to the ﬁrst documented disease progression on
radiological or clinical assessment, or to death from any cause.
PFS was censored at the time of last radiological disease assessment
in subjects who did not progress or die, and at the date of the ﬁrst
dose of study drug in subjects who discontinued the study with no
post-treatment tumour assessment. Kaplan–Meier curves were
produced for all mesothelioma subjects together and separately
by Merlin status.
RESULTS
Demographics and subject disposition
Thirty-four subjects were enrolled and received at least one dose
of combination treatment. Of eight subjects who discontinued
the study, seven withdrew consent and one was removed at the
investigator’s discretion. Thirty-two subjects were included in
the pharmacokinetic population and 21 in the pharmacody-
namic cohort. Patient characteristics are shown in Supplemen-
tary Table 1. The mean ( ± SD) age of subjects was 64.4 years ( ±
9.95); 22 subjects (65%) were aged ≥65 years. Most subjects (n
= 33; 97%) were white. Mesothelioma was the most common
tumour type (n= 21; 62%).
Determination of the MTD
Table 1 summarises doses and DLTs. Two of three subjects
receiving trametinib 1 mg QD/GSK2256098 500 mg BID developed
DLTs. As a result, the trametinib dose was reduced to 0.5 mg QD
for Cohort 2, with GSK2256098 maintained at 500mg BID. Of
seven subjects enrolled, six were evaluable, and DLTs developed
in two of these six subjects. Five subjects in Cohort 3 received
trametinib 0.5 mg QD/GSK2256098 250 mg BID; one subject
developed a DLT. Five additional subjects were enrolled at this
dose for pharmacodynamic assessments. In Cohort 4, four subjects
received trametinib 0.25 mg QD/GSK2256098 500mg BID. Three
subjects were evaluable, but none developed DLTs. Four
additional subjects were enrolled at this dose for pharmacody-
namic assessments. Cohort 5 had four subjects treated with
trametinib 0.375 mg QD/GSK2256098 500mg BID; one subject
had a DLT. Two additional subjects were enrolled for pharmaco-
dynamic assessment; there were no additional DLTs.
The high GSK2256098/low trametinib MTD was determined to
be 500 mg BID/0.375 mg QD and the low GSK2256098/high
trametinib MTD as 250mg BID/trametinib 0.5 mg QD.
Safety
All subjects reported at least 1 AE. AEs occurring in ≥20% of all
subjects were nausea (59%), diarrhoea (53%), decreased appetite
(38%), pruritus, fatigue (both 29%), rash (26%), vomiting (24%),
and asthenia, cough, or acneiform dermatitis (21% each) (Table 2
and Supplementary Table 2). There were no grade 4 AEs. Twenty
subjects (59%) had ≥1 Grade 3 AE; diarrhoea (n= 3), asthenia
(n= 3), decreased appetite (n= 2), and fatigue (n= 2) were most
common.
Fourteen subjects developed serious AEs, most commonly
diarrhoea (n= 2), lower respiratory tract infection (n= 2), nausea
(n= 2), and vomiting (n= 2), although none of these were
considered related to GSK2256098; 15% of subjects had an SAE
that could be attributed to trametinib. Sixteen subjects (47%) had
≥1 AE leading to dose interruption. Seventeen percent of subjects
in the group receiving high GSK2256098/low trametinib (500 mg
BID/0.375mg QD) had an AE causing dose interruption
compared with 60% in the low GSK2256098/high trametinib
(250 mg BID/0.5 mg QD) group. Five subjects had a dose reduction
due to non-serious AEs, with no notable differences across
dose groups. The trametinib dose was reduced in three subjects,
the GSK2256098 dose in one, and the dose of both agents in
another.
Pharmacokinetics and pharmacodynamics
Peak plasma concentration (Cmax) and area under the
concentration-time curve over the dosing interval (AUC(0-τ)) were
generally dose proportional for both agents (Table 3). Trametinib
exposure (Cmax and AUC) was 2- to 4-fold higher when
Table 1. Summary of dose-limiting toxicities
Cohort Treatment No. of subjects treated No. of subjects with DLTs
1 GSK2256098 500mg BID+ trametinib 1.0 mg
QD
3 2 – Grade 3 rash (pustular) - Grade 3 rash (dermatitis acneiform)
2 GSK2256098 500mg BID+ trametinib 0.5 mg
QD
7 2 – Grade 3 decreased appetite - Grade 3 fatigue, Grade 3 rash
(maculopapular)
3 GSK2256098 250mg BID+ trametinib 0.5 mg
QD
10 1 – Grade 3 ejection fraction decreased
4 GSK2256098 500mg BID+ trametinib
0.25mg QD
8 0
5 GSK2256098 500mg BID+ trametinib
0.375mg QD
6 1 – Grade 2 dermatitis (acneiform)
BID twice daily, DLT dose-limiting toxicity, PD pharmacodynamics, PK pharmacokinetics, QD once daily
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administered with GSK2256098 versus trametinib monotherapy
data (Table 3). The exposure of GSK2256098 was not altered when
co-administered with trametinib. The median time to Cmax (tmax)
for GSK2256098 was generally 2 h post-dose for GSK2256098 and
1.5 to 2.5 h post-dose for trametinib. The tmax of trametinib was
slightly delayed with GSK2256098 co-administration.
There was good agreement between dried blood spot and
whole blood concentrations of GSK2256098 (Table 3).
Paired biopsies were available for eight subjects and phos-
phorylated FAK (pFAK)/FAK was determined for six; two subjects
with insufﬁcient post-dose tumour tissue were not evaluable.
Three of six subjects showed >70% decrease in pFAK/FAK
from baseline; two showed >45% reduction in pFAK/FAK levels.
The remaining subject demonstrated an increased pFAK/FAK ratio
(Table 4). pERK data were obtained in only three of the eight
subjects showing a divergent trend: two subjects had >70%
inhibition of pFAK and >60% inhibition of pERK (Fig. 1a;
example data for subject #200); the other had activation of pERK
(Fig. 1b; example data for subject #202). The remaining ﬁve
subjects had signals below the lower limit of quantiﬁcation. Merlin
status was determined for 18/21 archival tumour samples from
subjects with mesothelioma; 15 (71%) samples stained negative
for Merlin.
Clinical activity
No objective responses to treatment were reported. The best
response was stable disease in 13 subjects (38%). Median PFS
was 11.8 weeks (95% CI: 6.1, 24.1) for subjects with mesothe-
lioma. Median PFS for 14 mesothelioma subjects with Merlin-
negative tumours was 15.0 weeks (95% CI: 4.4, 24.1) and
7.3 weeks for 3 subjects with Merlin-positive tumours (CI not
calculable) (Fig. 2).
DISCUSSION
This is the ﬁrst clinical study evaluating the combination of FAK
and MEK inhibitors in subjects with cancer. Preclinical studies of
the combination demonstrated synergistic activity in several
tumour types, including mesothelioma, providing justiﬁcation for
evaluating this combination.
We used an adaptive design to allow simultaneous evaluation
of multiple dose levels, starting at 50% of the MTD of GSK2256098
and 50% of the recommended dose of trametinib.7,12 DLTs at the
ﬁrst dose level required dose de-escalation. Initially we assumed
that the excessive toxicity resulted from overlapping effects on
signal transduction pathways. However, pharmacokinetic analysis
showed that systemic exposure of trametinib was unexpectedly
high when co-administered with GSK2256098. After dose normal-
ization, the geometric mean Cmax and AUC for trametinib were 2-
to 4-fold higher when trametinib was administered concomitantly
with GSK2256098 compared with trametinib monotherapy.16 Our
data also suggest that tmax may be slightly delayed when
trametinib is co-administered with GSK2256098 relative to the
monotherapy tmax.
16 The pharmacokinetics of GSK2256098 were
unaffected by concomitant trametinib and were comparable to
those seen in a previous monotherapy study.7
Trametinib is metabolised predominantly via deacetylation
(non-CYP mediated) alone or with mono-oxygenation or in
combination with glucuronidation biotransformation pathways.
Although the enzyme responsible is unidentiﬁed, deacetylation is
likely mediated by hydrolytic esterases, such as carboxylesterases
or amidases. The mechanism of the pharmacokinetic interaction
between GSK2256098 and trametinib is not fully understood, but
in vitro investigation found that GSK2256098 inhibits deacetyla-
tion of trametinib by inhibiting human carboxylesterases
(eg, hCES1b, hCES1c, and hCES2) and potentially other esterases
Table 2. Adverse events occurring in ≥10% of patients, regardless of causality
Adverse event GSK2256098 250mg
BID+ 0.5 mg
trametinib QD
(N= 10)
GSK2256098 500mg
BID+ 0.25mg
trametinib QD
(N= 8)
GSK2256098 500mg
BID+ 0.375mg
trametinib QD
(N= 6)
GSK2256098 500mg
BID+ 0.5 mg
trametinib QD
(N= 7)
GSK2256098 500mg
BID+ 1.0 mg
trametinib QD
(N= 3)
Total
(N= 34)
Any event, n (%) 10 (100) 8 (100) 6 (100) 7 (100) 3 (100) 34 (100)
Nausea 5 (50) 4 (50) 3 (50) 5 (71) 3 (100) 20 (59)
Diarrhoea 5 (50) 3 (38) 4 (67) 3 (43) 3 (100) 18 (53)
Decreased appetite 4 (40) 1 (13) 2 (33) 5 (71) 1 (33) 13 (38)
Fatigue 2 (20) 3 (38) 1 (17) 2 (29) 2 (67) 10 (29)
Pruritus 3 (30) 3 (38) 0 1 (14) 3 (100) 10 (29)
Rash 3 (30) 2 (25) 0 2 (29) 2 (67) 9 (26)
Vomiting 1 (10) 1 (13) 1 (17) 4 (57) 1 (33) 8 (24)
Asthenia 2 (20) 0 3 (50) 2 (29) 0 7 (21)
Cough 2 (20) 2 (25) 2 (33) 1 (14) 0 7 (21)
Dermatitis acneiform 1 (10) 3 (38) 2 (33) 0 1 (33) 7 (21)
Constipation 3 (30) 2 (25) 0 0 0 5 (15)
Dyspnoea 1 (10) 2 (25) 1 (17) 1 (14) 0 5 (15)
Folliculitis 3 (30) 0 2 (33) 0 0 5 (15)
Anaemia 2 (20) 0 0 2 (29) 0 4 (12)
Gastro-oesophageal
reﬂux disease
1 (10) 1 (13) 0 2 (29) 0 4 (12)
Oedema peripheral 1 (10) 1 (13) 1 (17) 0 1 (33) 4 (12)
Grade 3 adverse events occurring in three subjects: diarrhoea, asthenia; Grade 3 adverse events occurring in two subjects: decreased appetite, fatigue; Grade 3
adverse events occurring in one subject: pruritus, dermatitis acneiform, constipation, dyspnoea, anaemia, increased serum creatinine, lower respiratory tract
infection, maculopapular rash, atrial ﬁbrillation, confusion, pulmonary embolism, acute myocardial infarction, cancer pain, dehydration, decreased ejection
fraction, bone metastases, neutropenia, pericardial effusion, pneumonitis, pneumothorax, pustular rash.
BID twice daily, QD once daily
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(GSK data on ﬁle). The increased trametinib plasma levels may
result from inhibition of its metabolic pathway. GSK2256098
also appears to impact trametinib’s absorption, based on the
delayed tmax in this study relative to historical trametinib
monotherapy data.16
Several strategies are used to determine doses of anticancer
agents administered in combination. Although it is tempting to
use the MTD of the more active agent and titrate up the
investigational agent until the MTD is identiﬁed, such an approach
in the current study could have resulted in life-threatening AEs.
Table 4. Pharmacodynamic response for pFAK in pre- and post-dose tumour samples
Subject No. Visit pFAK (CU/μg) Total FAK (CU/μg) pFAK/FAK % Change from baseline pFAK % Change from baseline pFAK/FAK
GSK2256098 250mg BID+ trametinib 0.5 mg QD
509 Baseline 112.070 1329.1 0.084 NA NA
Day 15 13.950 585.9 0.024 –87.6 –71.763
510 Baseline 92.400 103.3 0.895 NA NA
Day 15 60.860 245.7 0.248 –34.1 –72.310
202 Baseline 189.010 680.3 0.278 NA NA
Day 22 30.960 762.1 0.041 –83.6 –85.378
206 Baseline 99.580 207.3 0.480 NA NA
Day 22 50.110 59.2 0.846 –49.7 76.125
GSK2256098 500mg BID+ trametinib 0.25 mg QD
507 Baseline 72.750 1710.6 0.043 NA NA
Day 15 NA 1107.3 NA NA NA
121 Baseline 41.680 183.7 0.227 NA NA
Day 22 25.900 214.6 0.121 –37.9 –46.809
GSK2256098 500mg BID+ trametinib 0.375mg QD
118 Baseline 79.470 268.6 0.296 NA NA
Day 22 NA NA NA NA NA
GSK2256098 500mg BID+ trametinib 0.5 mg QD
200 Baseline 15.230 12.1 1.263 NA NA
Day 22 24.600 62.0 0.397 −61.5 –68.586
BID twice daily, FAK focal adhesion kinase, NA not available, pFAK phosphorylated FAK, QD once daily
Table 3. GSK2256098 and trametinib pharmacokinetic parameters after repeat dosing on Day 15
Cmax, ng/mL Geometric
mean (%CV)
tmax, h Median (range) AUC(0–τ), ng·h/mL
Geometric mean (%CV)
GSK2256098 pharmacokinetics when given in combination with trametinib (whole blood)
GSK2256098 250mg (n= 10) 1397 (71) 2.0 (1.5–4.1) 5467 (58)
GSK2256098 500mg (n= 21) 2453 (82) 2.0 (1.5–6.0) 10 410a (62)
GSK2256098 pharmacokinetics when given in combination with trametinib (dry blood spot)
GSK2256098 250mg (n= 6) 1229 (73) 2.8 (1.5–4.1) 4975 (57)
GSK2256098 500mg (n= 10) 2834 (44) 2.0 (1.5–4.0) 12 663 (27)
Trametinib pharmacokinetics when given in combination with GSK2256098 (plasma)
Trametinib 0.25mg+GSK2256098 500mg BID (n= 6) 6.23 (17) 2.5 (0.33–6.5) 122 (15)
Trametinib 0.375mg+GSK2256098 500mg BID (n= 6) 11.2 (47) 2.5 (2.0–6.0) 229 (43)
Trametinib 0.5 mg+GSK2256098 250mg BID (n= 10) 16.3 (35) 2.4 (0.50–6.5) 347b (33)
Trametinib 0.5 mg+GSK2256098 500mg BID (n= 6) 13.0 (27) 2.6 (0.62–4.8) 266 (26)
Trametinib 1.0 mg+GSK2256098 500mg BID (n= 3) 36.0 (11) 1.5 (1.5–6.5) 732 (22)
Trametinib pharmacokinetics when given as monotherapy (plasma)16
Trametinib 2.0 mg (n= 13) 22.2 (28) 1.75 (1.0–3.0) 370c (22)
AUC area under the concentration-time curve over the dosing interval, BID twice daily, Cmax, maximal plasma concentration, QD once daily, tmax time
to Cmax, % CV between-subject coefﬁcient of variation
an= 20
bn= 8
cAUC in this study was reported as 0–24 h
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Fortunately, by adjusting down the dose of trametinib, MTDs for
both low trametinib/high GSK2256098 and high trametinib/low
GSK2256098 combinations were determined. The clinical concen-
trations at these doses are within the range of those associated
with the in vitro gIC50 and dEC50 for both compounds.
6,17
Except at the initial dose levels, the overall safety of the
combination was acceptable. Of note was the better tolerability of
the high GSK2256098/low trametinib MTD versus the low
GSK2256098/high trametinib dose level.
The results of the present study showed almost equivalent effect
between GSK2256098+ trametinib combination and those from
an earlier GSK2256098 monotherapy study7 in terms of reduction
of FAK levels. The addition of trametinib did not show any clinically
relevant beneﬁt. Pharmacodynamic studies demonstrated that
GSK2256098 inhibited pFAK at the doses evaluated. An earlier
GSK2256098 monotherapy study similarly found that patients with
Merlin-negative mesothelioma had longer PFS than those
with Merlin-positive mesothelioma.7 The prognostic signiﬁcance
of Merlin status has been recently reported by Meerang.18
Meerang et al reported in two independent cohorts of mesothe-
lioma patients that low tumour Merlin expression is associated
with a poorer freedom from recurrence and poorer overall survival
than in mesothelioma patients with higher Merlin expression.
Despite low Merlin tumour expression being a negative prognostic
factor in patients with mesothelioma, our results suggest that
mesothelioma patients with absent or low Merlin expression have
a longer duration of treatment than Merlin-positive patients when
administered GSK2256098.18 These current ﬁndings conﬁrm the
prior monotherapy ﬁndings of GSK2256098.
A greater effect of FAK inhibition in Merlin-negative than
Merlin-positive mesothelioma tumours is consistent with
data showing that Merlin inactivation in mesothelioma cell
lines is related to invasiveness and upregulation of the FAK
pathway.19
In conclusion, we identiﬁed MTDs for a GSK2256098/
trametinib combination for use in future clinical studies. There
was, however, limited support for efﬁcacy of this combination in
these patients. We also highlight the importance of pharmaco-
kinetic monitoring and careful selection of starting doses during
phase Ib dose-escalation combination studies, even where no
pharmacokinetic interaction between investigational agents is
anticipated.
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Fig. 1 Pharmacodynamic response in tumour samples evaluated at baseline (pre-dose) and kpost-dosing of GSK2256098 and trametinib for
22 days. The expression level relative to baseline levels (normalized to 100%; Dark grey bars) of pFAK and pERK normalised to the level of FAK
in the sample. The ratio of the pFAK level relative to FAK and the pERK level relative to FAK are shown for each subject and are indicative of
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